Reproductive biology and IVF: Ovarian stimulation and luteal phase consequences

Trends in Endocrinology and Metabolism

Volumn 14, Issue 5, 2003, Pages 236-242

  Fauser, Bart C J M ^a   Devroey, Paul ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN ANTAGONIST;

CLINICAL PROTOCOL; CORPUS LUTEUM FUNCTION; ENDOMETRIUM; FERTILIZATION IN VITRO; FOLLICULAR PHASE; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; OOCYTE; OOCYTE MATURATION; OVARY; OVARY FOLLICLE; PRIORITY JOURNAL; REPRODUCTION; REVIEW; STIMULATION;

EID: 0038607405     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(03)00075-4     Document Type: Review

References (67)

1. Jennings, J.C. et al. (1996) In vitro fertilisation. A review of drug therapy and clinical management. Drugs 52, 313-343
2. Fauser, B.C. et al. (2002) Alternative approaches in IVF. Hum. Reprod. Update 8, 1-9
3. Huirne, J.A. et al. Contemporary pharmacological manipulation in assisted reproduction. Drugs (in press)
4. Fauser, B.C. et al. (1999) Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Hum. Reprod. 14, 2681-2686
5. Bancsi, L.F. et al. (2002) Predictors ofpoor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil. Steril. 77, 328-336
6. Beckers, N.G. et al. (2002) Women with regular menstrual cycles and a poor response to ovarian hyperstimulation for in vitro fertilization exhibit follicular phase characteristics suggestive of ovarian aging. Fertil. Steril. 78, 291-297
7. Edwards, R.G. et al. (1980) Establishing full-term human pregnancies using cleaving embryos grown in vitro. Br. J. Obstet. Gynaecol. 87, 737-756
8. Trounson, A.O. et al. (1981) Pregnancies in humans by fertilization in vitro and embryo transfer in the controlled ovulatory cycle. Science 212, 681-682
9. Wortham, J.W. et al. (1983) Vital initiation of pregnancy using human menopausal gonadotropin and human chorionic gonadotropin ovulation induction: phase II-1981. Fertil. Steril. 40, 170-177
10. Fauser, B.C. (1998) Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Hum. Reprod. 13 (Suppl. 3), 36-46
11. Out, H.J. et al. (1995) A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization. Hum. Reprod. 10, 2534-2540
12. Daya, S. (2002) Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil. Steril. 77, 711-714
13. Sykes, D. et al. (2001) The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments. Hum. Reprod. 16, 2557-2562
14. Dickey, R.P. et al. (2002) Comparison of the efficacy and safety of a highly purified human follicle-stimulating hormone (Bravelle) and recombinant follitropin-β for in vitro fertilization: a prospective, randomized study. Fertil. Steril. 77, 1202-1208
15. European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone, (2002) Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil. Steril. 78, 520-528
16. European Recombinant LH Study Group, (2001) Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J. Clin. Endocrinol. Metab. 86, 2607-2618
17. Beckers, N.G. et al. (2003) First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization. Fertil. Steril 79, 621-623
18. Westergaard, L.G. et al. (2000) Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum. Reprod. 15, 1003-1008
19. Fleming, R. et al. (2000) Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum. Reprod. 15, 1440-1445
20. Filicori, M. (2002) The potential value of mid-follicular phase LH. Hum. Reprod. 17, 517-520
21. Whelan, J.G. and Vlahos, N.F. (2000) The ovarian hyperstimulation syndrome. Fertil. Steril. 73, 883-896
22. Delvigne, A. and Rozenberg, S. (2002) A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum. Reprod. Update 8, 291-296
23. Al Inany, H. and Aboulghar, M. (2002) GnRH antagonist in assisted reproduction: a Cochrane review. Hum. Reprod. 17, 874-885
24. Out, H.J. et al. (2001) A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Hum. Reprod. 16, 1104-1109
25. Wikland, M. et al. (2001) A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum. Reprod. 16, 1676-1681
26. Fauser, B.C. and van Heusden, A.M. (1997) Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr. Rev. 18, 71-106
27. van Heusden, A.M. and Fauser, B.C. (2002) Residual ovarian activity during oral steroid contraception. Hum. Reprod. Update 8, 345-358
28. Hohmann, F.P. et al. (2001) Low-dose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development. Hum. Reprod. 16, 846-854
29. Hohmann, F.P. et al. (2003) A randomized comparison of two ovarian stimulation protocols with GnRH antagonist cotreatment for IVF commencing recombinant FSH on cycle day 2 or 5 with the standard long GnRH agonist protocol. J. Clin. Endocrinol. Metab. 88, 166-173
30. Janssens, R.M. et al. (2000) Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum. Reprod. 15, 2333-2340
31. Hugues, J.N. and Cedrin, D. (1998) Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins. Hum. Reprod. Update 4, 83-101
32. Bouchard, P. and Fauser, B.C. (2000) Gonadotropin-releasing hormone antagonist: new tools vs. old habits. Fertil. Steril. 73, 18-20
33. Elter, K. and Nelson, L.R. (2001) Use of third generation gonadotropin-releasing hormone antagonists in in vitro fertilization-embryo transfer: a review. Obstet. Gynecol. Surv. 56, 576-588
34. Albano, C. et al. (2000) Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum. Reprod. 15, 526-531
35. Borm, G. and Mannaerts, B. (2000) Treatment with the GnRH antagonist ganirelix in women undergoing ovarian stimulation with recombinant FSH is effective, safe and convenient: results of a controlled, randomized, multi center trial. Hum. Reprod. 15, 1490-1498
36. Fluker, M. et al. (2001) Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Hum. Reprod. 75, 38-45
37. Hernandez, E.R. (2000) Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum. Reprod. 15, 1211-1216
38. de Jong, D. et al. (2001) Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon). Fertil. Steril. 75, 688-693
39. Filicori, M. et al. (2001) Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J. Clin. Endocrinol. Metab. 86, 337-343
40. Shoham, Z. et al. (1995) The luteinizing hormone surge - the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil. Steril. 64, 237-251
41. Gonen, Y. et al. (1990) Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J. Clin. Endocrinol. Metab. 71, 918-922
42. Fauser, B.C. et al. (2002) Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J. Clin. Endocrinol. Metab. 87, 709-715
43. Simon, C. et al. (1998) Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone step-down regimen. Fertil. Steril. 70, 234-239
44. Duffy, D.M. et al. (1999) Titrating luteinizing hormone replacement to sustain the structure and function of the corpus luteum after gonadotropin-releasing hormone antagonist treatment in rhesus monkeys. J. Clin. Endocrinol. Metab. 84, 342-349
45. Casper, R.F. and Yen, S.S. (1979) Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor. Science 205, 408-410
46. Mais, V. et al. (1986) The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe. J. Clin. Endocrinol. Metab. 62, 1250-1255
47. Weissman, A. et al. (1996) Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation. Hum. Reprod. 11, 943-949
48. Jones, H.W. (1996) What has happened? Where are we? Hum. Reprod. 11 (Suppl. 1), 7-24
49. Smitz, J. et al. (1992) The effect of gonadotrophin-releasing hormone (GnRH) agonist in the follicular phase on in-vitro fertilization outcome in normo-ovulatory women. Hum. Reprod. 7, 1098-1102
50. Pritts, E.A. and Atwood, A.K. (2002) Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum. Reprod. 17, 2287-2299
51. Pantos, K. et al. (1994) Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program. Fertil. Steril. 61, 709-713
52. Frydman, R. et al. (1991) Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation. Fertil. Steril. 56, 923-927
53. Ragni, G. et al. (2001) Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Hum. Reprod. 16, 2258-2262
54. Beckers, N.G. et al. (2002) Comparison of the non-supplemented luteal phase characteristics after recombinant (r)HCG, rLH or GnRH agonist for oocyte maturation in IVF. Hum. Reprod. (Abstr.), O-157
55. Edwards, R.G. et al. (1996) Time to revolutionize ovarian stimulation. Hum. Reprod. 11, 917-919
56. Gerris, J. et al. (1999) Prevention of twin pregnancy after in-vitro fertilization or intracytoplasmic sperm injection based on strict embryo criteria: a prospective randomized clinical trial. Hum. Reprod. 14, 2581-2587
57. Martikainen, H. et al. (2001) One versus two embryo transfer after IVF and ICSI: a randomized study. Hum. Reprod. 16, 1900-1903
58. Strandell, A. et al. (2000) Selection of patients suitable for one-embryo transfer may reduce the rate of multiple births by half without impairment of overall birth rates. Hum. Reprod. 15, 2520-2525
59. Nygren, K.G. and Andersen, A.N. (2001) Assisted reproductive technology in Europe, 1998. Results generated from European registers by ESHRE. European society of human reproduction and embryology. Hum. Reprod. 16, 2459-2471
60. Toner, J.P. (2002) Progress we can be proud of: US trends in assisted reproduction over the first 20 years. Fertil. Steril. 78, 943-950
61. Macklon, N.S. and Fauser, B.C. (2000) Regulation of follicle development and novel approaches to ovarian stimulation for IVF. Hum. Reprod. Update 6, 307-312
62. Pelinek, M.J. et al. (2002) Efficacy of natural cycle IVF: a review of the literature. Hum. Reprod. Update 8, 129-139
63. Macklon, N.S. et al. (2002) Conception to ongoing pregnancy: the 'black box' of early pregnancy loss. Hum. Reprod. Update 8, 333-343
64. Kligman, I. and Rosenwaks, Z. (2001) Differentiating clinical profiles: predicting good responders, poor responders, and hyperresponders. Fertil. Steril. 76, 1185-1190
65. Collins, J. (2002) An international survey of the health economics of IVF and ICSI. Hum. Reprod. Update 8, 265-277
66. Hillier, S.G. et al. (1985) Superovulation strategy before in vitro fertilization. Clin. Obstet. Gynaecol. 12, 687-723
67. Oehninger, S. and Hodgen, G.D. (1990) Induction of ovulation for assisted reproduction programmes. Baillieres Clin. Obstet. Gynaecol. 4, 541-573